Alprostadil injection in treating 56 patients with chronic liver failure observed in patients with liver fibrosis.docVIP

 PAGE \* MERGEFORMAT 10 Alprostadil injection in treating 56 patients with chronic liver failure observed in patients with liver fibrosis Of: Li Li-chun Xu Lei Wang Ping Fang Ju Jinchang [Abstract] Objective of this study was to investigate alprostadil injection (Lipo-PGE1 treatment of chronic liver failure the clinical effects of hepatic fibrosis. Methods A total of 104 patients with chronic liver failure were randomly divided into treatment group of 56 patients in the control group 48 cases control group received routine liver protection, anti-virus, jaundice and symptomatic and supportive treatment, the treatment group received conventional treatment, in addition, plus alprostadil injection 10g, intravenous drip, qd, 4 weeks for a course of treatment, observation of hepatic fibrosis of index changes and adverse reactions. Results treatment group was 69.6%, 45.8% in the control group, liver fibrosis treatment group improved significantly better than the control group, the incidence of hepatorenal syndrome was significantly lower than the control group (all P lt;0.05 , adverse reactions. Conclusion alprostadil injection for the treatment of viral liver fibrosis in chronic liver failure, an effective anti-drug. [Keywords:] chronic viral liver failure alprostadil 1 Materials and Methods 1.1 Clinical data from January 2006 we have ~ February 2010, we collected 104 cases of chronic liver failure patients (all HBsAg positive, HBeAg-negative, HBcAg-positive, excluding a Bingding HEV), are in line with lt;lt;Journal of Medicine 2006 Credit will be infected with diseases of liver failure and liver disease treatment guidelines credits will begt;gt; the diagnostic criteria. 56 patients were randomly divided into treatment group and control group 48 cases, of which 45 cases treated male and 11 female, mean age 47 + -3 years old the control group, male 39, female 9, mean age 46 + -4 .2-year-old patients in the sex, age, ascites volume and no significant d